Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Google Secures Pentagon AI Deal for Classified Projects 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
NEW YORK, Feb. 03, 2016 -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Interim Chief Executive Officer, will present at the 18th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City. The presentation is scheduled to take place on Monday, February 8, 2016 at 1:00pm EST. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at www.tgtherapeutics.com.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the Company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has a pre-clinical program to develop IRAK4 inhibitors, as well as an antibody research program to develop anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.
TGTX - G
CONTACT: Jenna Bosco Director- Investor Relations TG Therapeutics, Inc. Telephone: 212.554.4351 Email: [email protected]
